<DOC>
	<DOCNO>NCT01740024</DOCNO>
	<brief_summary>The primary objective clinical trial quantify loss vivo biological potency depigmented polymerize ( DPP ) allergenic cat epithelial extract versus native allergenic extract ( N ) .</brief_summary>
	<brief_title>Biological Potency Cat Epithelial Allergenic Extracts</brief_title>
	<detailed_description>This open-label , non-randomized phase II clinical trial . Three different concentration three different cat epithelial allergenic extract , together positive negative control , use 10 mg/ml histamine dihydrochloride glycerated phenol saline solution , respectively , test every subject volar surface forearm .</detailed_description>
	<criteria>A subject eligible inclusion study follow criterion meet : The subject ( and/or legal representative , applicable ) give write , sign date informed consent . Subjects either sex race ethnic group . Age &gt; 18 year &lt; 60 year day inclusion study . Positive clinical history allergy cat epithelium ( i.e. , rhinitis , conjunctivitis , rhinoconjunctivitis , asthma , urticaria , etc . ) . A positive pricktest ( mean diameter papule ≥ 3 mm area papule ≥ 7 mm2 ) commercial extract cat epithelium . The result pricktest valid obtain year prior inclusion subject study . A positive specific IgE test ( &gt; 0.70 KU/l ) cat epithelium . The result IgE test valid obtain year prior inclusion subject study . A subject NOT eligible inclusion study follow criterion meet : Immunotherapy last 5 year involve allergen know able interfere test allergen ( e.g. , cat extract ) . Use drug interfere skin response study ( e.g. , antihistamine ) , within interval establish section 9.1 appendix 1 . Treatment follow medicine : tricyclic tetracyclic antidepressant MAOIs ( Monoamine oxidase inhibitor ) , betablockers chronic use oral corticosteroid use corticosteroid via either oral parenteral route repeat intermittent dosing regimen ( &gt; 10 mg/day prednisone equivalent ) . Pregnant nursing woman woman positive pregnancy test visit 2 . Dermographism affect skin test site , either two visit study centre . Atopic dermatitis affect skin test site , either two visit study centre . Urticaria affect skin test site , either two visit study centre . Clinically relevant immune system disease ( autoimmune disorder immune deficiency ) . ( Hashimoto 's thyroiditis hypothyroidism well control thyroid hormone therapy necessarily represent contraindication . Graves ' disease ( hyperthyroidism ) would exclusion criterion due potential risk event adrenaline must use . ) Serious uncontrolled disease may increase safety risk subject participate study , include limited following : heart failure , serious uncontrolled respiratory disease , endocrine disorder , clinically relevant liver kidney disease , haematological disorder . Patents diseases condition limit adrenaline use ( coronary disease , severe arterial hypertension , etc. ) . Serious psychiatric , psychological neurological problem . Medication , alcohol illegal drug abuse last year . Participation clinical trial 30 day ( 5 time biological halflife investigational product whichever long ) prior inclusion subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Subcutaneous immunotherapy</keyword>
	<keyword>Skin Prick Test</keyword>
	<keyword>Dose Response Prick Test</keyword>
</DOC>